Management of glucocorticoids-induced osteoporosis: role of teriparatide

References

• CushingHThe basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism)Bull Johns Hopkins Hosp193250137195
   Google Scholar
• LukertBGlucocorticoid-induced osteoporosisMarcusRFeldmanDKelseyJOsteoporosisAcademic PressSan Diego, CA1996801820
   Google Scholar
• FitzpatrickLAGlucocorticoid-induced osteoporosisMarcusROsteoporosisBlackwell Scientific PublicationsBoston, MA1994202226
   Google Scholar
• NIH Consensus Development Panel on Osteoporosis prevention, diagnosis, and therapyOsteoporosis prevention, diagnosis, and therapyJAMA20012857859511176917
   PubMed Web of Science ®Google Scholar
• WeinsteinRSGlucocorticoid-induced osteoporosisRev Endocr Metab Disord20012657311708295
   PubMedGoogle Scholar
• LukertBPRaiszLGGlucocorticoid-induced osteoporosis: pathogenesis and treatmentAnn Intern Med19901123443462306063
   PubMed Web of Science ®Google Scholar
• LoCascioVBonucciEImbimboBBone loss in response to long-term glucocorticoid therapyBone Miner1990839512306553
   PubMedGoogle Scholar
• SteinbuchMYouketTECohenSOral glucocorticoid use is associated with an increased risk of fractureOsteoporos Int20041532332814762652
   PubMed Web of Science ®Google Scholar
• DempsterDBone histomorphometry in glucocorticoid-induced osteoporosisJ Bone Miner Res198941371412658477
   PubMed Web of Science ®Google Scholar
• Dalle CarbonareLGianniniSBone microarchitecture as an important determinant of bone strengthJ Endocrinol Invest2004279910515053252
   PubMed Web of Science ®Google Scholar
• MigliaccioSFalconeSSperaGBone modeling and remodeling: from biology to clinical applicationAgeing Clin Exp Res200719S510
   Google Scholar
• WeinsteinRSJilkaRLParfittAMManolagasSCInhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on boneJ Clin Invest19981022742829664068
   PubMed Web of Science ®Google Scholar
• O’BrienCAJiaDPlotkinLIGlucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strengthEndocrinology20041451835184114691012
   PubMed Web of Science ®Google Scholar
• HeitzerMDWolfIMSanchezERWitchelSFDeFrancoDBGlucocorticoid receptor physiologyRev Endocr Metab Disord2007832133018049904
   PubMed Web of Science ®Google Scholar
• BhargavaAPearceDMechanisms of mineralcorticoid action: determinants of receptor specificity and actions of regulated gene productsTrends Endocrinol Metab20041514715315109612
   PubMed Web of Science ®Google Scholar
• MigliaccioSMarinoMEstrogens and estrogen receptors: new actors in the plot of transcriptional regulation of genomic responsesCalcif Tissue Int20037218118212522666
   PubMed Web of Science ®Google Scholar
• LipworthBJTherapeutic implications of non-genomic glucocorticoid activityLancet2000356878910963239
   PubMed Web of Science ®Google Scholar
• PlotkinLIManolagasSCBellidoTGlucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival. Evidence for inside-out signaling leading to anoikisJ Biol Chem2007282241202413017581824
   PubMed Web of Science ®Google Scholar
• BeavanSHornerABordSIrelandDCompstonJColocalization of glucocorticoid and mineralcorticoid receptors in human boneJ Bone Miner Res2001161496150411499872
   PubMed Web of Science ®Google Scholar
• HuangLXuJKumtaSMZhengMHGene expression of glucocorticoid receptor α and β in giant cell tumor of bone: evidence of glucocorticoid-stimulated osteoclastogenesis by stromal-like tumor cellsMol Cell Endocrinol200118119920611476953
   PubMed Web of Science ®Google Scholar
• WongMMRaoLGLyHHamiltonLTongJSturtridgeWLong-term effects of physiologic concentrations of dexamethasone on human bone-derived cellsJ Bone Miner Res199058038132173356
   PubMed Web of Science ®Google Scholar
• BeresfordJNJoynerCJDevlinCTriffittJTThe effects of dexamethasone and 1,25dihydroxyvitamin D3 on osteogenic differentiation of human bone marrow stromal cells in vitroArch Oral Biol1994399419477695507
   PubMed Web of Science ®Google Scholar
• ChengSLYangJWRifasLZhangSFAvioliLVDifferentiation of human bone marrow osteogenic stromal cells in vitro: induction of osteoblastic phenotype by dexamethasoneEndocrinology19941342772868275945
   PubMed Web of Science ®Google Scholar
• CooperMSHewisonMStewardPM1999Glucocorticoid activity, inactivity and the osteoblastJ Endocrinol16315916410556763
   PubMed Web of Science ®Google Scholar
• DelanyAMGabbitasBYCanalisECortisol downregulates osteoblast α-1(I) procollagen mRNA by transcriptional and posttranscriptional mechanismsJ Cell Biochem1995574884947768983
   PubMed Web of Science ®Google Scholar
• BuxtonECYaoWLaneNEChanges in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1–34)J Clin Endocrinol Metab2004893332333615240611
   PubMed Web of Science ®Google Scholar
• LeclercNLuppenCAHoVVGene expression profiling of glucocorticoid-inhibited osteoblastsJ Mol Endocrinol20043317519315291752
   PubMed Web of Science ®Google Scholar
• OlkkuABodinePVLinnala-KankkunenAMahonenAGlucocorticoids induce glutamine synthetase expression in human osteoblastic cells: a novel observation in boneBone20043432032914962810
   PubMed Web of Science ®Google Scholar
• OhnakaKTaniguchiHKawateHNawataHTakayanagiaRGlucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosisBiochem Biophys Res Comm200431825926415110782
   PubMed Web of Science ®Google Scholar
• Van StaaTPLeufkensHGAbenhaimLZhangBCooperCUse of oral corticosteroids and risk of fracturesJ Bone Miner Res200015993100010841167
   PubMed Web of Science ®Google Scholar
• BolingEPSecondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosisClin Ther2004111414996513
   PubMed Web of Science ®Google Scholar
• MazziottiGAngeliABilezikianJPCanalisEGiustinaAGlucocorticoid-induced osteoporosis: an updateTrends Endocrinol Metab20061714414916678739
   PubMed Web of Science ®Google Scholar
• WallachSCohenSReidDMEffects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapyCalcif Tissue Int20006727728511000340
   PubMed Web of Science ®Google Scholar
• CosmanFParathyroid hormone treatment for osteoporosisCurr Opin Endocrinol Diabetes Obes20081549550118971677
   PubMed Web of Science ®Google Scholar
• KaufmanJMGoemaereSOsteoporosis in menBest Pract Res Clin Endocrinol Metab20082278781219028357
   PubMed Web of Science ®Google Scholar
• BlickSDDhillonSKeamSJTeriparatide: a review of its use in osteoporosisDrugs2008682709273719093708
   PubMed Web of Science ®Google Scholar
• JilkaRLMolecular and cellular mechanisms of the anabolic effect of intermittent PTHBone2007401434144617517365
   PubMed Web of Science ®Google Scholar
• DoggettTASwarthoutJTJefcoatSCJrParathyroid hormone inhibits c-jun N-terminal kinase activity in rat osteoblastic cells by a protein kinase A-dependent pathwayEndocrinology20021431880188811956171
   PubMed Web of Science ®Google Scholar
• SabatiniMLesurCPacherieMEffects of parathyroid hormone and agonists of the adenylyl cyclase and protein kinase C pathways on bone cell proliferationBone19961859658717538
   PubMed Web of Science ®Google Scholar
• Gesty-PalmerDChenMReiterEDistinct beta-arrestin and G-protein-dependent pathways for parathyroid hormone receptor-stimulated ERK ½ activationJ Biol Chem2006281108561086416492667
   PubMed Web of Science ®Google Scholar
• DobnigHTurnerRTEvidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cellsEndocrinology1995136363236387628403
   PubMed Web of Science ®Google Scholar
• JilkaRLO’BrienCAAliAARobersonPKWeinsteinRSManolagasSCIntermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblastsBone2008
   PubMed Web of Science ®Google Scholar
• JilkaRLWeinsteinRSBellidoTRobersonPParfittAMManolagasSCIncreased bone formation by prevention of osteoblast apoptosis with parathyroid hormoneJ Clin Invest199910443944610449436
   PubMed Web of Science ®Google Scholar
• WangBLDaiCLQuanJXParathyroid hormone regulates osterix and Runx2 mRNA expression predominantly through protein kinase A signaling in osteoblast-like cellsJ Endocrinol Investig20062910110816610234
   PubMed Web of Science ®Google Scholar
• DattaNSPettwayGJChenCKohAJMcCauleyLKCyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cellsJ Bone mineral Res200722951964
   PubMed Web of Science ®Google Scholar
• CanalisEGiustinaABilezikianJPMechanisms of anabolic therapies for osteoporosisN Engl J Med200735790591617761594
   PubMed Web of Science ®Google Scholar
• GarrettIRAnabolic agents and the bone morphogenetic protein pathwayCurr Dev Top Biol200778127171
   PubMed Web of Science ®Google Scholar
• KakarSEinhornTAVoraSEnhanced chondrogenesis and Wnt signaling in PTH-treated fracturesJ Bone Mineral Res20072219031912
   PubMed Web of Science ®Google Scholar
• KabackLASoung doYNaikATeriparatide (1–34 human PTH) regulation of osterix during fracture repairJ Cell Biochem200810521922618494002
   PubMed Web of Science ®Google Scholar
• BodinePVSeestaller-WehrLKharodeYPBexFJKommBSBone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1J Cell Physiol200721035235717044082
   PubMed Web of Science ®Google Scholar
• BlalockSJNortonLLPatelRADooleyMAPatient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosisArthritis Rheum20055373273916208664
   PubMed Web of Science ®Google Scholar
• van StaaTPLeufkensHGAbenhaimLBegaudBZhangBCooperCUse of oral corticosteroids in the United KingdomQJM20009310511110700481
   PubMed Web of Science ®Google Scholar
• CompstonJUK guidelines for glucocorticoid-induced osteoporosis: similarities and differencesCurr Rheumatol Rep20046666914713404
   PubMedGoogle Scholar
• AbadieECDevogealerJPRingeJDRecommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in ScienceSemin Arthritis Rheum2005351416084217
   PubMed Web of Science ®Google Scholar
• PereiraRGDelanyAMCanalisEEffects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expressionBone20023068569111996905
   PubMed Web of Science ®Google Scholar
• RosenCJWhat’s new with PTH in osteoporosis: where are we and where are we headedTrends Endocrinol Metab2004152293315223053
   PubMed Web of Science ®Google Scholar
• SeemanEReduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosisOsteoporos Int200314S2S812730770
   PubMed Web of Science ®Google Scholar
• LaneNESanchezSGenantHKJenkinsDKArnaudCDShort-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosisOsteoporosis Int200011434442
   PubMed Web of Science ®Google Scholar
• RehmanQLangTFArnaudCDModinGWLaneNEDaily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosisOsteop Int2003147781
   PubMed Web of Science ®Google Scholar
• SaagKGShaneEBoonenSTeriparatide or alendronate in glucocorticoid-induced osteoporosisN Engl J Med20073572028203918003959
   PubMed Web of Science ®Google Scholar
• LosadaBRZanchettaJRZerbiniCActive comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from Hispanic and non-hispanic cohortsJ Clin Densitom2008
   PubMed Web of Science ®Google Scholar
• BuxtonECYaoWLaneNEChanges in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1–34)J Clin Endocrinol Metab200489333233615240611
   PubMed Web of Science ®Google Scholar
• LaneNESanchezSModinGWGenantHKPieriniEArnaudCDBone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trialJ Bone Miner Res20001594495110804025
   PubMed Web of Science ®Google Scholar
• SaagKZanchettaJDevogelaerJAdlerRSeeKDalskyGTeriparatide or alendronate in glucocorticoid-induced osteoporosis: data from 36 months trialAnnual Congress of the Am Soc Bone Mineral Res Abs20081171
   Google Scholar